NVCT Latest Press Releases

-- December 17, 2025 --

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC Globe Newswire 7:00 AM

-- November 25, 2025 --

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC Globe Newswire 8:00 AM

-- November 4, 2025 --

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights Globe Newswire 8:15 AM

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights Globe Newswire 7:30 AM

-- October 27, 2025 --

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Globe Newswire 8:00 AM

-- October 16, 2025 --

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Globe Newswire 8:00 AM

-- September 25, 2025 --

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors Globe Newswire 8:00 AM

-- September 4, 2025 --

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software